A. Engin

Endocrinology, Diabetes and Metabolism · 2017

A researcher in the Science corpus: 1 paper; trusts 2 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom A. Engin trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. E. Ford
  2. R. Ervin
  3. M. Blüher
  4. S. Grundy

Papers from A. Engin's perspective

Ordered by how strongly the researchers A. Engin trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. (Journal of Clinical Endocrinology and Metabolism)
  2. Identification and characterization of metabolically benign obesity in humans. (Archives of Internal Medicine)
  3. Cardiovascular morbidity and mortality associated with the metabolic syndrome. (Diabetes Care)
  4. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. (Diabetes Care)
  5. Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition (Arteriosclerosis, Thrombosis and Vascular Biology)
  6. Relationship between adipocyte size and adipokine expression and secretion. (Journal of Clinical Endocrinology and Metabolism)
  7. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. (American Journal of Epidemiology)
  8. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. (The Lancet)
  9. Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement Executive Summary (Critical Pathways in Cardiology)
  10. 10-year follow-up of intensive glucose control in type 2 diabetes. (New England Journal of Medicine)

Their papers